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outcomes in high-risk patients.
OBJECTIVES TAVR complication rates were evaluated based on prospective data from the German Aortic Valve
Registry (GARY).
METHODS From 2011 to 2013, a total of 15,964 TAVR procedures were registered. We evaluated the total cohort for severe
vital complications (SVCs), including the following: death on the day of intervention, conversion to sternotomy, low cardiac
output that required mechanical support, aortic dissection, and annular rupture; technical complications of the procedures
(TCOs), such as repositioning or retrieval of the valve prosthesis and embolization of the prosthesis; and other complications.
RESULTS Mean patient age was 81  6 years, 54% of the patients were women, the median logistic Euroscore I was
18.3, the German aortic valve score was 5.6, and the Society of Thoracic Surgeons score was 5.0. Overall in-hospital
mortality was 5.2%, whereas SVCs occurred in 5.0% of the population. Independent predictors for SVCs were female sex,
pre-operative New York Heart Association functional class IV, ejection fraction <30%, pre-operative intravenous ino-
tropes, arterial vascular disease, and higher degree of calciﬁcations. TCOs occurred in 4.7% of patients and decreased
signiﬁcantly from 2011 to 2013. An emergency sternotomy was performed in 1.3% of the patients; however, multivariate
analysis did not identify any predictors for conversion to sternotomy.
CONCLUSIONS The all-comers GARY registry revealed good outcomes after TAVR and a regression in complications.
Survival of approximately 60% of patients who experienced SVCs or who required sternotomy underlines the need for
heart team–led indication, intervention, and follow-up care of TAVR patients. (J Am Coll Cardiol 2015;65:2173–80)
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ABBR EV I A T I ON S
AND ACRONYMS
AV = aortic valve
IQR = interquartile range
EF = ejection fraction
MI = myocardial infarction
NYHA = New York Heart
Association
PCI = percutaneous coronary
intervention
s/p = status post
STS = Society of
Thoracic Surgeons
SVCs = severe vital
complications
TAVR = transcatheter aortic
valve replacement
TCO = technical complications
of the procedure
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2174O ver the past 10 years, transcatheteraortic valve replacement (TAVR)has reached widespread clinical
acceptance as treatment for elderly and
high-risk patients with aortic stenosis (1,2).
After an initial learning curve, the clinical
outcomes of patients after TAVR procedures
have improved in parallel with a steady
decrease in complication rates (3). This
may be explained by the increasing clinical
experience of the physicians who perform
the implantations, improvements in patient
screening using speciﬁc imaging strategies
(including computed tomography assess-
ment of the target areas), better patient selec-
tion that excludes less feasible patients from
these therapies, and technical improvements
in the individual transcatheter valve pros-
theses and their application systems (4–8).SEE PAGE 2181Despite all of these achievements, TAVR pro-
cedures are associated with a considerable remaining
risk. Complications such as malposition or displace-
ment of the valve prosthesis, hemodynamic insta-
bility requiring cardiocirculatory support, coronary
artery occlusions, aortic annular ruptures, aortic dis-
sections, ventricular perforations, arrhythmias, aortic
regurgitation, sternotomy, stroke, death, or need for
permanent pacemaker implantation have been re-
ported, among others (9,10). At present, these risks
vary between 3% and 8% depending on the risk pro-
ﬁles of the patients, the overall clinical experience of
the teams, and the type of analyses (i.e., whether they
are calculated for selected trials or all-comers expe-
riences) (11–15). The overall assessment of a relatively
new therapeutic procedure like TAVR should be
based on population-wide results, which can only be
gathered by speciﬁc clinical registries. Analysis of
such registry data will paint a more realistic picture of
the performance and complication rates of a new
procedure in the “real world.”
Taking these ﬁndings into consideration, we
analyzed the acute and in-hospital incidence of speciﬁc
complications associated with TAVR procedures from
the all-comers German Aortic Valve Registry (GARY).
We speciﬁcally focused on the potential for a decrease
incomplicationsover timeduetoa learningcurveeffect
and on the potentially predictive risk factors that could
be associated with speciﬁc complications.
METHODS
GARY was designed as an all-comers registry for pa-
tients treated for aortic valve disease from July 2010to 2015. Details have been reported previously
(16–18). All-comers data from 88 sites are included in
this registry. All contributing sites had sufﬁcient
previous clinical experience with TAVR procedures.
In total, 4% of the procedures were performed at sites
without a department of cardiac surgery but with a
cardiac surgeon on standby.
Registry data, derived in part from the mandatory
quality control, were carefully entered into the data-
base and then checked for completeness and consis-
tency. Thereafter, the database was ﬁnalized for the
analysis. All further calculations were compiled at an
independent medical research institution, the BQS
Institute for Quality and Patient Safety (Düsseldorf,
Germany). Acute complications from 2011 to 2013
were analyzed in the subset of 15,964 patients who
underwent TAVR. Most patients underwent retro-
grade transfemoral TAVR (n ¼ 11,292; 70.7%) or
anterograde transapical TAVR (n ¼ 4,304; 27%),
whereas 368 patients (2.3%) were treated by an
alternative access route. In-hospital outcome data of
these patients were analyzed.
Complications were deﬁned according to their
complexity and the direct consequences for the pa-
tient. We evaluated the following groups:
 All patients, total;
 Severe vital complications (SVCs): death on the day
of intervention, conversion to sternotomy, acute
percutaneous coronary intervention (PCI), low
cardiac output requiring mechanical circulatory
support, cardiac tamponade requiring treatment,
aortic dissection, or annular rupture;
 Technical complications of the procedures (TCOs):
repositioning or retrieval of the valve prosthesis,
valve-in-valve procedure, valve embolization, or
closure of a paravalvular leak;
 Other complications: aortic regurgitation, new-
onset pacemaker implantation, stroke, major vas-
cular complications, and major bleeding;
 Conversion to sternotomy; and
 In-hospital death.
Multiple parameters were prospectively included
in the database and subsequently analyzed regarding
their potential impact on observed complications.
Pre-operative patient characteristics included fe-
male sex, age, logistic Euroscore, German aortic valve
(AV) score, Society Thoracic Surgeons (STS) score
(2008 valve mortality model), body mass index, New
York Heart Association (NYHA) functional status,
coronary artery disease, status post (s/p) myocardial
infarction (MI), s/p PCI, previous cardiac surgery,
pulmonary hypertension, hypertension, diabetes,
atrial ﬁbrillation, chronic obstructive pulmonary
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2175disease, ejection fraction (EF), cardiac decompensa-
tion, cardiogenic shock, renal replacement therapy,
long-term renal replacement therapy, on ventilator,
neurological dysfunction, inotropes, arterial vascular
disease, peripheral arterial vascular disease, aortic
valve opening area, mean and maximum aortic valve
pressure gradient, degree of aortic valve calciﬁcation,
mitral regurgitation $2, porcelain aorta, previous
valvuloplasty, previous pacemaker/deﬁbrillator, bi-
cuspid aortic valve, degree of aortic stenosis and
regurgitation, and tricuspid regurgitation.
We also analyzed the following procedural/
operative data: elective procedure, general anes-
thesia, access for TAVR, balloon dilation, rapid pacing
for implantation, cardiopulmonary bypass used,
conversion to open heart surgery, cardiac tamponade,
major vascular complication, residual aortic regur-
gitation $2, new-onset pacemaker implantation,
stroke, major bleeding, duration of the procedure,
radiation time, and contrast dye use.
STATISTICS. The primary endpoint of the study was
intrahospital mortality; SVCs and TCOs were sec-
ondary endpoints. Categorical variables are presented
in percentages, and continuous scaled variables are
presented as mean  SD. Score results are given as
median and interquartile range (IQR). A univariate
analysis was performed using the chi-square test for
categorical variables and the Mann-Whitney U testTABLE 1 Baseline Clinical and Echocardiographic Characteristics
TAVR
2011–2013
Total
(N ¼ 15,964)
SVC
(n ¼ 792)
Patients 100.0 5.0
Female 54.1 59.5*
Age, yrs 80.9  6.1 81.0  6.2
Log Euroscore 18.3 (11.0–30.5) 21.0* (12.0–36.2
German AV score 5.6 (3.3–9.1) 6.1* (3.8–11.0)
STS score 5.0 (3.4–7.7) 5.7* (3.8–8.7)
NYHA functional class III– IV 86.1 88.0
CAD 55.1 58.0
Previous cardiac surgery* 21.0 23.0
Pulmonary hypertension 35.7 35.6
COPD requiring medication 14.2 12.8
EF <30% 9.5 12.8*
Renal replacement therapy 5.0 4.8
PVD 19.5 22.3*
Aortic oriﬁce
area, cm2
0.70  0.28 0.67  0.3*
Pmean, mm Hg 44  17 45  18
Values are %, mean  SD, or median (interquartile range). *p < 0.05 versus total.
AV¼ aortic valve; CAD ¼ coronary artery disease; COPD¼ chronic obstructive pulmona
aortic pressure gradient; PVD ¼ peripheral vascular disease; STS ¼ Society of Thorac
replacement; TCO ¼ technical complications.and Kruskal-Wallis test for continuous variables.
Two-sided p values < 0.05 were considered statisti-
cally signiﬁcant. The variables conﬁrmed to be asso-
ciated with an endpoint were included in a backward
stepwise logistic regression analysis for identifying
independent predictors for primary and secondary
endpoints. All test statistics and backward stepwise
procedures were performed using the statistical
computer package SPSS version 22 (SPSS Inc., Chi-
cago, Illinois).RESULTS
A total of 15,964 patients were included in this anal-
ysis. The mean age was 80.9  6.1 years, and 54.1%
were women. A balloon-expandable prosthesis (SA-
PIEN XT, SAPIEN 3, Edwards Lifesciences Inc., Irvine,
California) was used in 8,390 patients (52.6%), a self-
expandable Corevalve prosthesis (Medtronic Inc.,
Minneapolis, Minnesota) was used in 6,026 patients
(37.7%), and other self-expandable prostheses were
used in 1,548 patients (9.7%). The main baseline
clinical and echocardiographic data are given in
Table 1. Patients who experienced SVCs or TCOs,
required sternotomy, or who died had signiﬁcantly
higher values for the EuroSCORE, German AV score,
and STS score. Procedural and post-operative data are
listed in Table 2.TCO
(n ¼ 748)
Sternotomy
(n ¼ 201)
Death
(n ¼ 828)
4.7 1.3 5.2
47.6* 59.2 53.4*
81.0  6.0 80.5  5.6 81.6  6.3
) 21.5* (12.7–35.6) 20.6 (11.4–36.0) 24.7* (14.4–44.2)
6.1* (3.3–10.4) 5.8* (3.7–10.9) 8.1* (4.6–14.3)
5.5* (3.8–8.0) 5.5*(3.8–8.2) 6.9* (4.6–11.4)
86.1 88.6 90.2*
58.2 50.2 61.8*
25.1* 19.4 23.3
35.9 34.2 45.4*
13.8 11.9 16.2
13.6* 8.5 16.3*
5.2 5.5 8.2*
19.7 22.4 30.1*
0.73  0.3 0.70  0.3 0.69  0.3*
42  17* 46  18 42  19*
ry disease; EF¼ ejection fraction; NYHA¼ New York Heart Association; Pmean¼mean
ic Surgeons; SVC ¼ severe vital complications; TAVR ¼ transcatheter aortic valve
TABLE 2 Procedural and Post-operative Data
TAVR
2011–2013
Total
(N ¼ 15,964)
SVC
(n ¼ 792)
TCO
(n ¼ 748)
Sternotomy
(n ¼ 201)
Death
(n ¼ 828)
In-hospital mortality 5.2 40.8* 17.1* 42.3* 100.0*
CPB used 2.4 28.7* 13.9* 56.7* 13.6*
Conversion to
open heart surgery
1.3 25.4* 12.0* 100.0* 10.3*
Cardiac tamponade 1.0 20.7* 3.9* 31.5* 8.0*
Transfemoral approach 70.7 66.3* 79.0* 67.7 58.6*
Transapical approach 27.0 31.3* 20.2* 30.3 37.6*
Other complications
Residual aortic
regurgitation $2
5.8 10.7* 12.8* 16.7* 12.0*
New-onset pacemaker
implantation
17.5 13.3* 25.2* 12.8 13.9*
Stroke 1.5 4.2* 4.1* 3.5* 6.3*
Major vascular complication 4.1 8.0* 10.3* 7.0* 8.0*
Major bleeding 26.3 54.7* 40.3* 70.1* 59.8*
Values are %. *p < 0.05 versus total.
CPB ¼ cardiopulmonary bypass; other abbreviations as in Table 1.
TABLE 3
Year
2011
2012
2013
p value
Values are n
Abbreviat
Walther et al. J A C C V O L . 6 5 , N O . 2 0 , 2 0 1 5
GARY Registry Acute TAVR Complications M A Y 2 6 , 2 0 1 5 : 2 1 7 3 – 8 0
2176COMPLICATIONS. Table 3 provides the overall inci-
dence of complications from 2011 to 2013. An average
5% of the patients (n ¼ 792) experienced SVCs, with a
signiﬁcant decrease in SVCs from 6.8% (in 2011) to
4.9% (in 2012) and 3.9% (in 2013) (p < 0.001). TCOs
occurred in 4.7% of patients and showed a similarly
signiﬁcant decline over the years from 5.3% (in 2011)
to 5.0% (in 2012) and 4.0% (in 2013) (p ¼ 0.003). The
overall survival of patients was 59.2% after a SVC (n ¼
469/792) and 82.9% after a TCO (n ¼ 620/748). The
number of patients who required sternotomy showed
a slight regression at 1.6% (in 2011), 1.2% (in 2012),
and 1.1% (in 2013) without statistical signiﬁcance (p ¼
0.133). There was some regression in the proportion
of patients who died in hospital at 5.9% (in 2011), 5%
(in 2012), and 4.9% (in 2013) without reaching statis-
tical signiﬁcance (p ¼ 0.078).
A total of 828 patients (5.2%) died during the pro-
cedures or during the hospital stay (Tables 1 to 3).
Among those, 160 patients (1% of the total patient
population) died on the day of intervention. PatientsOverall Incidence of Complications
TAVR
Total SVC TCO Sternotomy Death
15,964 (100%) 792 (5.0%) 748 (4.7%) 201 (1.3) 828 (5.2%)
3,945 (100) 270 (6.8) 209 (5.3) 62 (1.6) 232 (5.9)
5,531 (100) 270 (4.9) 279 (5.0) 65 (1.2) 277 (5.0)
6,488 (100) 252 (3.9) 260 (4.0) 74 (1.1) 319 (4.9)
– <0.001 0.003 0.133 0.078
(%).
ions as in Table 1.who died were signiﬁcantly different from all other
patients; they were frequently men; in NYHA func-
tional classes III to IV; had coronary artery disease,
s/p MI, s/p PCI, pulmonary hypertension, diabetes,
atrial ﬁbrillation, EF <30%, cardiogenic shock or
decompensation; were receiving renal replacement
therapy; were on ventilators; were receiving intra-
venous inotropes; and had arterial and peripheral
vascular disease, mitral regurgitation $2, porcelain
aorta, or had undergone previous balloon valvulo-
plasty. They also had a higher logistic Euroscore,
German AV score, STS score, mean and maximum
gradients, and smaller aortic opening areas. Patients
who died periprocedurally had signiﬁcantly higher
rates of general anesthesia, cardiopulmonary bypass,
conversion to open heart surgery, cardiac tamponade,
intraprocedural vascular complications, and residual
aortic regurgitation $2, as well as longer procedural
duration.
Multivariate independent predictors of death
included (Table 4) residual aortic regurgitation $2,
peripheral vascular disease, mitral regurgitation >2,
EF <30%, pulmonary hypertension, NYHA functional
class IV, body mass index <22 kg/m2, low cardiac
output, cardiogenic shock, TCOs, sternotomy, post-
operative stroke, post-operative new-onset dialysis,
post-operative MI, post-operative ischemia, aortic
dissection, annular rupture, tamponade, PCI due to
complications, and bleeding. Multivariate analysis
showed that the transapical approach was not an in-
dependent predictor of death.
A total of 792 patients (5%) experienced at least 1
SVC (Tables 1 and 2). These 792 patients were 81  6
years old, 59.5% were women, the logistic Euroscore
was 21.0 (IQR 12.0 to 36.2), the German AV score was
6.1 (IQR 3.0 to 11.0), and the STS score was 5.7 (IQR 3.8
to 8.7). The observed SVCs were conversion to ster-
notomy (n ¼ 201; 1.3%), PCIs (n ¼ 70; 0.4% of the total
patient population), low cardiac output that required
mechanical circulatory support (n ¼ 228; 1.4%), tam-
ponade (n ¼ 164; 1%), aortic dissection (n ¼ 33; 0.2%),
and aortic annular rupture (n ¼ 68; 0.4%).
There were signiﬁcantly higher numbers of pa-
tients with SVCs who had the following pre-operative
patient characteristics: female sex; logistic Euro-
score; German AV score; NYHA functional class IV;
EF <30%; cardiac decompensation or cardiogenic
shock; pre-procedural use of inotropes; arterial
vascular disease; peripheral vascular disease; smaller
aortic valve oriﬁce area; maximum pressure gra-
dient; heavy degree of calciﬁcations; mitral regur-
gitation $2; previous balloon valvuloplasty; and
grade IV aortic stenosis (Table 1). Patients with SVCs
also had a signiﬁcantly higher incidence of these
TABLE 4 Odds Ratios for Death Derived From Multivariate Analysis
OR 95% CI p Value
Residual aortic regurgitation $2 1.885 1.372–2.588 0.000
PVD 1.443 1.156–1.800 0.001
Mitral regurgitation >2 1.324 1.079–1.624 0.007
EF <30% 1.573 1.184–2.092 0.002
Pulmonary hypertension 1.353 1.106–1.655 0.003
NYHA functional class IV 1.288 0.999–1.661 0.051
Body mass index <22 kg/m2 1.586 1.227–2.049 0.000
Low cardiac output 8.850 6.039–12.971 0.000
Cardiogenic shock 1.952 1.296–2.941 0.001
Technical complications 1.638 1.155–2.323 0.006
Sternotomy 2.078 1.208–3.573 0.008
Post-operative stroke 3.574 2.301–5.550 0.000
Post-operative new-onset dialysis 10.519 8.137–13.599 0.000
Post-operative myocardial infarction 23.146 10.877–49.251 0.000
Post-operative ischemia 2.101 1.085–4.068 0.028
Aortic dissection 5.594 2.023–15.470 0.001
Annular rupture 7.058 3.202–15.559 0.000
Tamponade 3.743 2.121–6.606 0.000
PCI due to complications 2.841 1.253–6.439 0.012
Bleeding 5.005 3.961–6.325 0.000
CI ¼ conﬁdence interval; OR ¼ odds ratio; PCI ¼ percutaneous coronary intervention;
other abbreviations as in Table 1.
TABLE 5 Odds Ratios for Various Complications Derived From
Multivariate Analysis
OR 95% CI p Value
Independent predictors for SVC
Female 1.37 1.16–1.62 0.0002
NYHA class IV 1.46 1.19–1.79 0.0003
LVEF #30% 1.33 1.05–1.70 0.0183
IV inotropes 3.88 2.92–5.16 0.0000
Arterial vascular disease 1.23 1.04–1.45 0.0159
Higher degree of calciﬁcation 1.28 1.07–1.52 0.0059
Higher degree of aortic stenosis 1.36 1.14–1.62 0.0007
Independent predictors for TCO
Year of procedure 0.882 0.803–0.969 0.009
Male 1.287 1.106–1.499 0.001
LVEF <30% 1.39 1.11–1.74 0.005
Neurological dysfunction 1.43 1.17–1.74 0.000
Cardiac decompensation 1.21 1.04–1.41 0.015
IV inotropes 2.22 1.59–3.11 0.000
IV ¼ intravenous; LVEF ¼ left ventricular ejection fraction; other abbreviations as
in Tables 1 and 4.
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2177procedural parameters: nonelective procedures;
use of general anesthesia; use of cardiopulmonary
bypass; conversion to open heart surgery; tampo-
nade; vascular complications; residual aortic re-
gurgitation $2; prolonged procedural duration; and
longer radiation time (Table 2).
In univariate and multivariate logistic regression
analyses, female sex, NYHA functional class IV,
EF #30%, the need for preoperative inotropic medi-
cation, peripheral vascular disease, a higher degree of
aortic valve calciﬁcation, and aortic stenosis of 4
were independent predictors of the occurrence of
SVCs (Table 5).
Technical complications occurred in 748 patients
(4.7%) (Table 2). This included valve-in-valve im-
plantation (n ¼ 295; 1.8% of the total population),
repositioning of the valve prosthesis (n ¼ 161; 1%),
retrieval of the valve prosthesis (n ¼ 146; 0.9%),
closure of a paravalvular leak (n ¼ 50; 0.3%), device
embolization (n ¼ 55; 0.3%; 43 of those had another
TCO in parallel), and sequential valve implantation
(n ¼ 84; 0.5%).
Patients who experienced TCOs were signiﬁcantly
different from all other patients concerning these
variables; they were less frequently women; had a
higher logistic Euroscore and a higher German AV
score; had a higher incidence of previous cardiac
surgery; more frequently had an EF <30%; were more
frequently on ventilators; more frequently received
inotrope therapy; had lower mean and maximum
pressure gradients; had lower degree of calciﬁcations;
and more frequently exhibited grade 4 aortic stenosis
and aortic regurgitation (Table 1). Periprocedural re-
sults revealed that patients with TCOs had signiﬁ-
cantly higher rates of cardiopulmonary bypass,
conversion to open heart surgery, tamponade, intra-
procedural vascular complications, residual aortic
regurgitation $2, longer duration of the procedure,
increased radiation time, and increased contrast dye
use (Table 2). They also had signiﬁcantly lower rates
of balloon dilation and rapid pacing for implantation.
In the multivariate assessment, independent
predictors for TCOs were male sex, EF <30%, neuro-
logical dysfunction, cardiac decompensation, and
intravenous inotrope therapy (Table 5). In addition, a
learning curve was apparent because the incidence of
TCOs decreased over the years (Table 3).
Residual aortic regurgitation $2 occurred in 5.8%
of patients, with a signiﬁcant decrease from 6.3% (in
2011) to 6.1% (in 2012) and 5.1% (in 2013) (p < 0.001).
New-onset pacemaker implantation occurred in 17.5%
of patients, with a similar decline from 19.5% (in 2011)
to 17.3% (in 2012) and 16.5% (in 2013) (p ¼ 0.008).
Stroke was diagnosed in 1.5%, and declined from2.0% (in 2011) to 1.3% (in 2012) and 1.4% (in 2013)
(p ¼ 0.014). Major vascular complications occurred in
4.1% and showed a similarly signiﬁcant decline over
the years, from 5.4% (in 2011) to 2.7% (in 2012) and
4.4% (in 2013) (p < 0.001). Major bleeding ($2 red
blood cell units) was present in 26.3% of the patients
(Table 2), with a signiﬁcant decline from 30.6%
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(p < 0.001). Patients who experienced SVCs or TCOs,
who died, or who required sternotomy had signiﬁ-
cantly higher rates of residual aortic regurgi-
tation $2, stroke, major vascular complications, and
major bleeding.
Conversion to sternotomy was required in 201 pa-
tients (1.3%), with some regression over time that did
not reach statistical signiﬁcance (p ¼ 0.133) (Table 3).
Patients who required sternotomy presented with a
signiﬁcantly higher incidence of a high German AV
score and receipt of intravenous inotropic therapy
and had a signiﬁcantly lower incidence of a porcelain
aorta (Table 1). They underwent elective procedures
less frequently; were treated with general anesthesia
more frequently; had a higher use of cardiopulmo-
nary bypass; more frequently experienced tampo-
nade, intraprocedural vascular complications, and
aortic regurgitation $2; and had longer procedural
duration and radiation time (all p < 0.05) (Table 2).
Survival of patients who required conversion to
sternotomy was 57.7% (n ¼ 116/201).
Univariate and multivariate analyses of these data
excluded any predictors for the potential occurrence
of sternotomy during a TAVR procedure.
Stroke occurred in a total of 1.5% (242/15,964)
of the patients (Table 2). It was signiﬁcantly more
frequent in patients who experienced SVCs (4.2%;
p < 0.001), in patients with TCOs (4.1%; p < 0.001), in
patients who required sternotomy (3.5%; p ¼ 0.034),
and in patients who died (6.3%; p < 0.001).
SCORES. The logistic Euroscore I was 18.3 (IQR: 11.0
to 30.5), the German AV score was 5.6 (IQR: 3.3 to 9.1),
and the STS score was 5.0 (IQR: 3.4 to 7.7) for the
overall population. All score values were signiﬁcantly
higher in patients with SVCs, TCOs, or who died (all
p < 0.001). According to all 3 scores, a regression in
risk proﬁles was observed over the years, The Euro-
score I went from a median of 20.2 (in 2011) to 18.6 (in
2012) and 16.9 (in 2013); the German AV score went
from 5.8 (in 2011) to 5.6 (in 2012) and 5.2 (in 2013); and
the STS score decreased from 5.2 (in 2011) to 5.0 (in
2012) and 4.9 (in 2013) (all p < 0.001).
DISCUSSION
The clinical application of new therapeutic tech-
niques like TAVR is usually associated with height-
ened enthusiasm and new perspectives, because
improved therapeutic options can be offered, espe-
cially to elderly and high-risk patients with relevant
aortic stenosis. However, despite all the optimism,
potential complications of a new procedure like TAVR
have to be critically evaluated as well. We haveseveral options to evaluate speciﬁc outcomes and
potential complications of TAVR procedures, in-
cluding well-documented randomized clinical trials
that may include a selected patient population only
(19–21), single- or multicenter nonrandomized studies
(22), and broader registry data (23–26) that may lack
some information on potential speciﬁc clinical de-
tails. In this regard, we believe that, despite all limi-
tations a clinical registry may have, particularly with
concerns about data quality, the magnitude and va-
riety of data in this prospective registry allowed us to
obtain a clear clinical picture of the advantages of the
new TAVR therapies and their potential complica-
tions. In addition, because TAVR therapies have been
performed in Germany with large numbers of patients
since 2008, the GARY registry data from the year 2010
onward permitted the assessment of real-world out-
comes for patients who underwent any invasive
therapy for aortic valve disease without any major
effects from the early learning curve (16–18).
Our present analysis yielded several major ﬁnd-
ings. First, we determined that TAVR therapy is safe
with acceptable complication rates in an all-comers
and high-risk patient population. The GARY registry
provided substantial data on 15,964 patients that
underline these ﬁndings. We also found that the
numbers of SVCs and TCOs signiﬁcantly decreased
over the years, but remained at approximately 4%
(Central Illustration). The reduction in complications
could be explained by continuous learning, improved
patient screening and appropriate selection, and
technical progress that included improved prosthetic
heart valves and application systems. Our analysis
further revealed signiﬁcant, independent predictors
for the occurrence of complications, especially pa-
tient sex, reduced EF, and arterial vascular disease,
among others.
In addition, the 1.3% incidence of conversion to
sternotomy was acceptably low without any signiﬁ-
cant changes over the years. Predictors for this
complication were not identiﬁed, despite a very large
number of patients. Finally, the overall in-hospital
death rate of 5.2% was acceptable and did not
change signiﬁcantly over the years examined. Twenty
independent predictors for death were determined,
as summarized in Table 3.
SVC, TCO, AND OTHER COMPLICATIONS. SVCs dur-
ing TAVR procedures included major challenges for
the entire heart team involved in treating these
patients. Therefore, it was encouraging to observe
that there was a signiﬁcant decrease in SVCs over
the years. However, the current incidence of these
complications is still appreciable and remains at
approximately 4%, despite the large clinical
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From 2011 to 2013, a total of 15,964 transcatheter aortic valve replacement (TAVR)
procedures were registered in the German Aortic Valve Registry (GARY). After evaluating
the total cohort for severe vital complications (SVCs), technical complications of the
procedures (TCOs), and other complications, including sternotomy and death, it was
determined that the incidence of SVCs and TCOs decreased signiﬁcantly from year to year,
but remained at approximately 4%. No changes were observed for need for sternotomy
(approximately 1.2%) and for in-hospital death (approximately 5%).
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2179experience that is available throughout Germany at
many speciﬁc sites that perform TAVR procedures.
Based on these numbers, we suggest that TAVR
should remain a heart team–led procedure performed
by anesthesiologists, cardiologists, and cardiac sur-
geons. The continuing use of experienced heart
teams, together with optimal infrastructure and
standard operating processes, will be the only way
forward to further minimize and eventually manage
such complications.
The signiﬁcant decrease in TCO rates that were
observed in this analysis most certainly reﬂect several
factors that are associated with current TAVR thera-
pies: 1) there is an increasing awareness of speciﬁc
patient assessment, screening, and pre-operative
imaging that has led to a good matching of the cho-
sen valve prosthesis to the individual patient; 2) the
clinical experience of many TAVR physicians has
increased steadily, and together with good heart team
cooperation, has led to a continuous improvement for
most of the procedures; and 3) signiﬁcant technical
developments with newer generation valve pros-
theses and steadily improved application systems,
which lead to smaller proﬁles, easier positioning,
and improved valve placement, have been estab-
lished. All of these changes clearly took place over
time and have led to improved outcomes with regard
to technical complications, even in complex TAVR
procedures.
The presence of aortic valve regurgitation $2
was acceptably low (5.8%) in this all-comers popula-
tion, especially because this condition is associated
with increased mortality in the intermediate post-
operative period (27,28). The incidence of new-onset
pacemaker implantation of 17.5% was rather high,
and was shown to be associated with TAVR and
with the choice of prosthetic valve to be implanted
(29). However, for the acute performance of the
procedures, we believe that this is only of minor
importance.
SURVIVAL AFTER COMPLICATIONS. Overall survival
rates were 59.2% (SVCs), 82.9% (TCOs), and 57.7%
(sternotomy). In view of some signiﬁcant complica-
tions that were present especially in the SVC, TCO,
and sternotomy groups, these survival rates were
quite encouraging. Without direct heart team therapy
on site, some of these patients might have died;
therefore, to decrease complications and optimize
outcomes TAVR should be performed by an estab-
lished heart team with an appropriate infrastructure.
STUDY LIMITATIONS. There were several limitations
to the present study, and these were especially related
to the nature of a registry: all-comers data could onlybe captured by a registry, but such data might lack
some of the details as well as the correlated adjudica-
tion that a randomized trial might have.
CONCLUSIONS
In the all-comers GARY registry, patients attained
good outcomes after TAVR and experienced a re-
gression in complications over time. SVCs and TCOs
of TAVR procedures remained at 4%, need for ster-
notomy remained at 1.2% without any predictors, and
the in-hospital death rate remained at 5% in this high-
risk population. However, survival rates, particularly
for patients who experienced SVCs or who required
sternotomy were promising (approximately 60%),
which demonstrated the continuing need for heart
team–led indication, intervention, and follow-up care
of TAVR patients.
ACKNOWLEDGMENTS The authors acknowledge the
support of Mrs. E. Schäfer, BQS Institute, for project
management. The authors are also very thankful to
Dr. E. Martinson for proofreading and editing the
paper. The authors thank the German Heart Founda-
tion for their unrestricted ﬁnancial support of the
Registry.
REPRINT REQUESTS AND CORRESPONDENCE: Prof.
Dr. Thomas Walther, Kerckhoff Herzzentrum, Klinik für
Herzchirurgie, Benekestrasse 2-8, D-61231 Bad Nauheim,
Germany. E-mail: t.walther@kerckhoff-klinik.de.
PERSPECTIVES
COMPETENCY IN PRACTICE-BASED LEARNING:
In Germany, a registry of all TAVR procedures found that
in-hospital mortality occurred in 5% of cases, other life-
threatening complications in 4%, and conversion to open
cardiac surgery in 1.2% of patients. Technical complica-
tions associated with adverse clinical outcomes dimin-
ished in relation to length of experience in performing the
procedure.
TRANSLATIONAL OUTLOOK: Further research is
needed to identify clinical features that predict the
need for conversion to sternotomy, allowing initial
recommendation of surgical valve replacement for these
patients and further reduction in complication rates for
those undergoing TAVR.
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